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This report of the Whole Genome Analysis group of
the Association for Molecular Pathology illuminates
the opportunities and challenges associated with clin-ical diagnostic genome sequencing. With the reality of
clinical application of next-generation sequencing,
technical aspects of molecular testing can be accom-
plished at greater speed and with higher volume,
while much information is obtained. Although this
testing is a next logical step for molecular pathology
laboratories, the potential impact on the diagnostic
process and clinical correlations is extraordinary and
clinical interpretation will be challenging. We review
the rapidly evolving technologies; provide application
examples; discuss aspects of clinical utility, ethics, and
consent; and address the analytic, postanalytic, and pro-
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The introduction of high-throughput, next-generation se-
quencing (NGS) in 2005 heralded a critical and transfor-
mative step in the history of DNA sequencing.1 NGS has
been broadly adopted by the biomedical research com-
munity as the method of choice for complex genomic
analyses, and NGS-based diagnostic testing for several
inherited disorders is available in a handful of clinical
laboratories. Before describing the conceptual essence
and utility of NGS, a brief reflection on the origins and
growth of sequencing is warranted. Two seminal articles,
describing the first methods for DNA sequencing, were
published in 1977. One was by Allan Maxam and Walter
Gilbert,2 who described an approach by which radioac-
tively end-labeled DNA fragments were subjected to
base-specific chemical cleavage, reaction products
were separated by gel electrophoresis, and subsequent
visualization was accomplished using film autoradiogra-
phy. In a second approach, Frederick Sanger and col-
leagues3 reported the use of chain-terminating dideoxy-
nucleotides that caused base-specific termination of
primed DNA synthesis. Although both approaches
yielded DNA sequences, the method developed by
Sanger’s group ultimately was more robust and amena-
ble to technical innovations. These first approaches in-
cluded supplanting radioactivity by fluorescently labeled
primers, followed by the development of fluorescently
labeled dideoxynucleotide chain terminators.4,5 In con-
junction, the conversion from slab gel to capillary elec-
trophoresis (CE) for resolving chain termination products
provided an additional foundational element that accel-
erated commercialization and dissemination of Sanger
sequencing and resulted in its gold standard status.6 The
deployment of Sanger sequencing in a factory-style con-
figuration culminated, in 2003, with the sequencing of the
first human genome under the auspices of the parallel
private efforts by Craig Ventor and the public Human
Genome Project at an estimated cost of $2.7 billion.7,8
This momentous accomplishment and historic milestone
must be interpreted in the context of our current sequenc-
ing capacity: with current NGS instrumentation, a human
genome can be sequenced in days for a reagent cost
that may soon be comparable to some of the more con-
ventional molecular diagnostic assays. This precipitous
decrease in cost and time to sequence at the genome
scale level has been technically realized by the conver-
gence of innovations in the chemistry, optics, fluidics,
computational hardware, and bioinformatics solutions
that underlie NGS. Although NGS platforms differ in de-
sign and specific chemistries, they are fundamentally
related by a paradigm in which sequencing of spatially
separated, clonally amplified DNA templates or single
DNA molecules is performed in a massively parallel man-
ner. A key feature is the sequencing of each clonal tem-
plate or single molecule, permitting enumeration of indi-
vidual sequences among all of the sequences generated.
The ability of NGS to generate high-throughput qualitative
and quantitative sequence information has enabled in-vestigations that were previously technically infeasible or
cost prohibitive. The diverse applications using NGS are
extensive and growing and include, among others, ge-
nome, transcriptome, and methylome sequencing, met-
agenomics, characterization of protein-nucleic acid inter-
actions, and targeted resequencing of multiple genes or
genomic regions identified during linkage and genome-
wide association studies (GWAS).
The power of NGS to generate hundreds of millions to
multigigabase levels of sequence in a single instrument
run, while having opened a diversity of research and
diagnostic avenues, is concomitantly stretching our abil-
ity to process data. This unprecedented amount of se-
quencing information poses bottlenecks that vary, de-
pending on application, at the level of data extraction,
analysis, and interpretation. These challenges have
become part and parcel of the biomedical research
community where investigators have increasingly
needed to incorporate bioinformatics and biostatistics
into their armamentarium. In a similar manner, clinical
laboratories developing and adopting NGS need to
build bioinformatics infrastructures composed of ex-
pertise and computational hardware. Indeed, the bal-
ance of time and effort required for NGS-based re-
search or diagnostics is substantially shifted toward
data analysis, as opposed to the technical component
required to generate the data.
We can anticipate for the foreseeable future that the
current NGS paradigm will continue to evolve with im-
provements in performance, accuracy, and instrumenta-
tion options that will further facilitate clinical translation.
Also emerging in this rapidly evolving field are physical
methods for sequencing based on biological or inorganic
nanopore methods. In the context of this dynamic evolu-
tion, it is timely to review and highlight the opportunities
and challenges that are experienced by clinical labora-
tories as they incorporate and leverage NGS for an ever-
increasing array of complex genomic analyses. Although
some laboratories are developing or using NGS for targeted
resequencing of multiple genes, there are also pioneering
laboratories that are performing clinical diagnostic exome
and genome sequencing. This report describes current
technical, bioinformatic, and clinical implementation con-
siderations, as well as medical applications, clinical utility,
and ethical, legal, and education issues presented by ge-
nome-level diagnostic testing.
NGS Technology
The NGS technologies are characterized by impressive
throughput; all offer the ability to simultaneously se-
quence thousands to millions of relatively short nucleic
acid sequences in parallel. The appeal is that they can
provide orders of magnitude more information, at com-
petitive costs, when large regions of the genome are
sequenced. For clinical applications, this becomes at-
tractive because individual sequencing assays based on
CE tend to be expensive, laborious, and less compre-
hensive, often necessitating serial gene-by-gene testing
to identify the causative mutation(s).
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types of chemistries, some of the platforms in use today
bear several similarities to Sanger-based CE. For exam-
ple, both methods begin with extracted DNA that is am-
plified. For CE methods, however, the PCR generally
occurs in a 96- (or a 384-) well microtiter plate or tubes
and is aimed at amplifying a limited number of regions.
NGS methods take advantage of the high-throughput
capabilities by targeting many more regions or a whole
genome. Targeted sequencing also can be accom-
plished through the use of multiplex (Fluidigm) or droplet
(Raindance) PCR or through pull-down methods in which
probes bind to specific regions, which are then amplified
and sequenced. For genome sequencing, the genomic
DNA (gDNA) is randomly sheared and fragments are size
selected by gel purification or solid-phase reversible im-
mobilization bead fractionation. Adaptors are attached to
the targeted primers and incorporated during PCR am-
plification or ligated to the DNA fragments themselves.
These adaptors are then physically bound in space to
beads, balls, or glass flow cells that have lawns of com-
plementary adaptor oligonucleotides. After a PCR-based
amplification, the individual clusters of amplified frag-
ments are simultaneously sequenced. These fragments
are typically shorter than usual CE fragments, although
length capabilities continue to increase. Although the
various NGS technologies use different types of chemis-
tries, in most cases, nucleotides used for the sequencing
reaction are fluorescently labeled and excited by a laser,
as with CE. A digital image is then captured for data
analysis. However, unlike CE, which uses dye-terminated
sequencing, the same labeled fragment can typically
have the fluorescent dye and blocker removed so that the
next nucleotide can be added. Because there are thou-
sands to millions of these reactions being performed next
to each other, this is referred to as massively parallel
sequencing. Platforms that have different chemistries or
methods include those that use native, fluorescently un-
labeled nucleotides and those in which sequence data
are obtained by either pyrophosphate-dependent chemi-
luminescence signal detection by a charge-coupled de-
vice camera or direct detection of ions produced by
template-directed synthesis on a massively parallel non-
optical semiconductor-sensing device (ion chip). Some
platforms skip the amplification step altogether and per-
form single-molecule sequencing in real time.
Different NGS technologies and their technological
and performance differences can be reviewed in articles
by Shendure and Ji,9 Voelkerding et al,10 Anderson and
Schrijver,11 Metzker,12 and Rothberg et al.13 However,
technology development occurs at a fast pace and ad-
ditional platforms are expected to emerge and add to the
options for application in clinical diagnostic laboratories.
Application Examples
Inherited Conditions
Monogenic conditions are caused by mutations that are
infrequent across the population. Before the availability ofa human genome reference sequence, disease genes
were sought by linkage analysis of large families with a
specific disease using markers mapped across the hu-
man chromosomes. This approach proved to be highly
successful for discovering monogenic conditions14–17
but not for complex disorders because of the difference
in strength of genotype-phenotype associations (effect
size). Being less direct than NGS, linkage analysis was
limited by the need for large pedigrees, densely mapped
markers, and clear clinical records, as well as by com-
plexities such as incomplete penetrance and modifier
genes. Triad analysis by sequencing the patient and
parental genomes or exomes using NGS will, in many
cases, be able to uncover the underlying pathogenic
mutation(s).
Since the completion of the Human Genome Project,
there has been a steady increase in the number of single-
gene disorders that have been elucidated. Some efforts
have focused on disease gene discovery, which inform
development of an appropriate clinical assay for the con-
dition. The use of NGS as a discovery tool can be illus-
trated by the identification of the MLL gene as a major
cause for autosomal-dominant Kabuki syndrome.18 In
other cases, a condition may be caused by any of a large
number of genes, and NGS approaches are able to
quickly hone in on the responsible gene, compared with
the one-by-one approach of traditional sequencing. In
such cases, the testing is less of a gene discovery effort;
rather, it is focused on finding the proverbial needle in the
haystack of previously identified genes.19 Genome se-
quencing is already being used as a clinical test for
patients with unidentified monogenic conditions in sev-
eral clinical centers, and reimbursement has been pro-
vided in at least one such instance. Until costs further
decrease, only those patients who are most likely to ben-
efit from genome or exome sequencing will typically be
offered this testing. Diagnostic challenges remain, how-
ever, especially when monogenic disorders arise be-
cause of novel missense mutations, structural aberra-
tions, germ-line or embryonic mosaicism, or imprinting
and other epigenetic factors. A major application of NGS
in testing for inherited disorders is in conditions such as
congenital disorders of glycosylation, hypertrophic car-
diomyopathy, developmental delay, neuromuscular dis-
orders, retinitis pigmentosa, and seizure disorders in
which the overlapping symptoms of multiple possible
syndromes and many potentially affected genes can
make an NGS approach cost-effective.
In contrast to the mutations in monogenic conditions,
risk loci for common, multifactorial diseases are more
frequently located in noncoding or intergene regions, and
the pathogenic mechanism of these variations is not well
understood.20 The availability of a reference human ge-
nome sequence led to cataloging of variants through the
International HAPMAP Project (http://hapmap.ncbi.nlm.
nih.gov, last accessed August 24, 2012), which identified
the linkage disequilibrium of 3.5 million single-nucleotide
polymorphisms (SNPs) across several populations. SNPs
and other variants are listed in the dbSNP Short Genetic
Variations database (http://www.ncbi.nlm.nih.gov/projects/
SNP, last accessed February 29, 2012), which contains
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characterization of SNPs, repeats, and linkage disequi-
libriums across chromosomes has enabled association
studies for the identification of disease genes in complex
common diseases, for which a population-based, rather
than a family-based, approach must be used to elucidate
genotype-phenotype correlations.21,22 In the past de-
cade, research on common complex diseases would fo-
cus on genotyping of a few candidate genes that were
hypothesized to be involved in the disease using a case-
control approach. There were a few success stories,
most notably the identification of apolipoprotein-4 allele
association in Alzheimer disease, but most results could
not be reproduced in subsequent analyses or in different
populations.23,24 The technological advance of dense
SNP chips has facilitated GWAS with many cases and
controls (1000 per group), and associations with can-
didate disease genes can be confirmed with subsequent
GWAS.20,22,25 Before the emergence of NGS technolo-
gies, multifactorial conditions were part of the diagnostic
test spectrum offered, but to a much lesser extent than
was the case for monogenic conditions. Given the com-
plexity of the clinical interpretation, many such conditions
were studied only on a research basis, rather than offered
in a clinical molecular diagnostic setting. Examples of
routine application, however, include the testing of se-
quence changes known to increase the risk of deep vein
thrombosis. Deep vein thrombosis is thought to have a
multifactorial etiology and is influenced by factors such
as ethnicity, sequence changes that confer genetic risk,
and socioeconomic differences.26
The Web site genome.gov22 catalogues 1200 poly-
morphisms that confer disease risk in 165 common
human diseases and traits. However, these variants typ-
ically confer low relative risk and predictive power. Even
when multiple risk markers are combined, the cumulative
risk scores are often comparable to traditional risk fac-
tors, such as family history and individual clinical profiles
(eg, cholesterol levels, age, sex, and obesity).27,28 These
markers were ascertained using population-based as-
sociations that may only apply to limited populations
and may lack clear biological meaning for any given
individual. Moreover, in almost all common diseases,
multiple risk alleles only explain approximately 5% of
the variance in the population, even when the disease
is considered highly heritable, leading to the concept
of missing heritability.29 The gene expression of these
multiple risk alleles with low predictive power may be
influenced by diet, environment, lifestyle, and epige-
netic factors. Nevertheless, even in patients with com-
mon diseases, NGS will permit the detection of rare
variants that would not be identified with SNP arrays,
which represent only the common variants used in
GWAS or with limited genotyping.
In the immediate future, the uncovering of three million
SNPs within an individual’s genome is only as useful as
our knowledge of what these SNPs signify. The full po-
tential of a DNA-based understanding of the common
complex diseases so prominent in the practice of medi-
cine can only be realized when the genome sequences of
thousands of individuals are available and linked to cor-responding phenotypes. Ultimately, data mining studies,
such as the U.K. 10,000 Genomes Project (Wellcome
Trust Sanger Institute; http://www.sanger.ac.uk/about/
press/2010/100624-uk10k.html, last accessed February
29, 2012), may lead to a refinement of disease pathways
and a better understanding of how specific alleles (rare
or common) present themselves as protective in health
and deleterious in disease.
Cancer: Diseases of Acquired, Somatic, and
Genetic Changes
During the past few years, knowledge of the molecular
mechanisms of cancer has markedly expanded as a
result of the identification of specific driver mutations and
other somatic changes, consequent alterations of gene
expression, and the discovery of the role of microRNAs in
carcinogenesis.30 As a consequence, the traditional his-
tological and immunohistochemical characterizations are
enhanced with respect to the classification of cancer
subtypes and by predictions of therapeutic response,
prognosis, and patient survival. Understanding the im-
portance of cancer target gene analysis has led to con-
siderable advances in drug therapies and has made
possible more personalized cancer treatment. Moreover,
the insight that the molecular profile of cancers is heter-
ogeneous, even within a single patient, may change dur-
ing the course of a patient’s disease, and affects the
acquired resistance to drugs, has transformed the field.
Multiple markers for specific cancers are being used to
stratify patients in clinical trials of new investigational
drugs, which are intended to be used for targeted inhi-
bition of cell proliferation.31,32 Response to treatment and
relapse are also being monitored in serial samples from
the patient through the detection of tumor-specific chro-
mosomal rearrangements and other genetic abnormali-
ties. Investigation of germ-line or constitutional cancer
predisposition markers that increase an individual’s risk
for developing cancer has contributed to screening and
patient management.33,34 The applications of NGS in on-
cology have ranged from mutation panel screening in
gene pathways to exome or transcriptome sequencing
and ultimately genome sequencing, with comparison to
the patient’s normal tissue or other reference sam-
ples.35–37 The concomitant availability of a complete ref-
erence sequence of the human genome has helped spur
massive coordinated initiatives, such as the Cancer Com-
mons (http://cancercommons.org, last accessed August
24, 2012), the International Cancer Genome Consortium
(http://www.icgc.org, last accessed February 29, 2012),
and the Cancer Genome Atlas (International Cancer Ge-
nome Consortium; http://cancergenome.nih.gov, last ac-
cessed February 29, 2012).38,39 These efforts have led to
extensive sequencing and cataloging of somatic muta-
tions and gene expression analyses in thousands of ge-
nomes from different classes of solid and hematological
cancers.40 As the number of known cancer markers in-
creases, it will likely be more cost-effective to profile a
patient’s tumor DNA using NGS than to conduct genetic
analysis for a growing set of mutations or to assay gene
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tissues. The quantitative nature of NGS technology is
another improvement over chip-based gene expres-
sion technologies. Recent use of gene expression
analysis for prognostic algorithms, such as Mam-
maprint (70 genes), OncotypeDX (21 genes), and Rot-
terdam signature (76 genes) will likely be replaced with
next-generation sequencing of signature tran-
scripts.41–43 Such information may be incorporated in
novel algorithms that use a patient’s somatic mutation
profile in addition to cancer susceptibility gene find-
ings. NGS will be transformative for diseases resulting
from somatic genetic changes because it will allow
speedy, cost-effective, and complete profiling of a pa-
tient’s tumor and germ-line DNA, transcriptome, and
DNA methylation profile in a single platform. However,
it is important to appreciate that different NGS plat-
forms have distinct capabilities of detecting DNA or
RNA sequence changes, DNA copy number changes,
DNA rearrangements, RNA expression changes, and
DNA methylation. The specific NGS method deter-
mines which combination of these changes can be
detected in either germ-line or tumor DNA. One
method will usually provide only part of this variety of
information. Therefore, a decision has to be made and
this may be based on cost, specimen availability, and
specimen quality, as well as the specific questions to
be answered.
Because of the significant false-positive rate associ-
ated with NGS,44 mutation confirmation in both inherited
diseases and neoplastic conditions is typically performed
using Sanger sequencing. However, confirmation on a
different NGS platform may also be considered. In the
future, independent confirmation may become increas-
ingly redundant, considering further evolution of the tech-
nology will undoubtedly facilitate a more complete char-
acterization of mutations. Compared with germ-line
sequencing, however, there are several specific chal-
lenges regarding somatic mutations. The percentage of
tumor cells within a sample varies, and the percentage of
tumor tissue with a mutation may vary, especially if it is a
(presumably) secondary mutation. A low percentage of
a secondary mutation in a tumor may overlap with the
false-positive rate identified by NGS. Low-level muta-
tions, however, cannot be easily confirmed by Sanger
sequencing, which has a higher threshold of detection
(approximately 15% to 20%) than NGS, without using a
more sensitive screening technique (eg, denaturing gradi-
ent gel electrophoresis or denaturing high-performance liq-
uid chromatography), an alternative approach (eg, pyrose-
quencing), or co-amplification at lower denaturation
temperature–PCR to enrich for the mutation.45–48 Another
challenge is the remarkable cancer genome complexity
reflected by the many different aberrations detected in
some tumors. Such heterogeneity within and between
tumors adds complexity to analytical validation and clin-
ical confirmation of identified mutations and personalized
therapeutic approaches. Thus, approaches and algo-
rithms different from those used in germ-line testing will
need to be developed for the applications in oncology.Clinical Utility
Aided by the rapidly decreasing cost of data generation,
large-scale personal genome sequencing will be applied
to a variety of settings and applications. With proper
interpretation, NGS will permit a deeper understanding of
disease mechanisms, allowing for more evidence-based
medical interventions. It will influence, to a greater de-
gree than possible with conventional molecular testing,
medical decisions, including personalized treatment of
disease, monitoring of disease progression, and as-
sessments of disease risk, prognosis, and reproduc-
tive matters; it is likely to affect the way in which indi-
viduals approach lifestyle questions.49 Although much
of this is likely to remain in the medical realm in which
physicians guide their patients to the testing best
suited for their medical management and to the appro-
priate interpretation, some genome testing will inevita-
bly be offered directly to consumers.50 In such a set-
ting, consumers will decide independently whether
they want to learn about topics ranging from ancestry
to disease risks. Thus, NGS will be relevant to both
patients and general consumers.
The personalized nature of testing at the genome level
includes a subjective assessment of the overall value of
the generated information. Apart from personal utility,
which could be defined as the perceived usefulness for
an individual given his or her interests (whether these are
medical or not), there is the issue of clinical utility. Clinical
utility is a measure of the net health benefits, reflected by
the balance of benefit versus harm. For an accurate eval-
uation of clinical utility, factors such as test rationale,
patient population, and clinical scenarios have to be con-
sidered. In addition, the principles of comparative effec-
tiveness should be followed. This requires an individual-
ized evidence-based approach for each patient,
ultimately accomplishing the separation of information
with demonstrated medical utility from information with
less clear or missing utility evidence.51,52 Some ques-
tions that are explored through NGS can be answered
with a high level of confidence, whereas others are com-
plex and require additional research. One of the com-
plexities is the assignment of pathogenicity of variants.
Even under the straightforward assumption of a single-
gene autosomal-recessive condition approached with
Sanger sequencing, the relationship of sequence vari-
ants to disease causation can be difficult to ascertain with
certainty. Given the data density of NGS, the issue of
variants of unknown significance is encountered many
times over, and our understanding of the biological,
pathophysiological, and functional impact of certain
genomic regions and sequence changes is still limited.
Thus, the development of evidence-based, validated scien-
tific standards to evaluate the clinical utility of genomic
results in different populations with accurate genotype-
based risk estimation is a considerable challenge. Further-
more, there is a possibility of potential overinterpretation of
results based on a limited understanding of contextual in-
formation that could lead to unnecessary medical action
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selection of patients for genome sequencing and concom-
itant genetic counseling are crucial.54
Informed Consent and Ethical Considerations
Informed consent is important to make the patient or
client aware of the benefits and harms that may occur as
a consequence of the testing process. For example, in-
cidental findings may suggest that the patient is at risk for
a disease that was not suspected. The capacity to per-
form large-scale sequencing on the human genome
presents unique challenges regarding the provision of
informed consent, particularly in deciding on the level of
detail that needs to be shared. No specific guidance
exists, and each institution offering such testing is deriv-
ing its own policies. Recently, concerns about genetic
discrimination have been focused mostly on predictive
testing for defined single-gene conditions, such as Hun-
tington disease and familial cancer syndromes. Genetic
nondiscrimination laws have been passed at both the
state and federal levels, offering some protection to indi-
viduals who carry deleterious sequence changes, in an
effort to alleviate concerns about potential abuse and
discrimination and to reduce societal obstacles to ge-
netic testing.
With genome testing by NGS, the perceived and real
potential risks are magnified compared with genetic tests
that target only one gene at a time.55 A patient who
undergoes genome sequencing will likely learn about
sequence variants of unknown clinical significance or
about other sequence changes that indicate disease risk
unrelated to the disease for which the testing was re-
quested. The potential for anxiety and uncertainty, result-
ing from results of unknown clinical significance, is asso-
ciated with any NGS method, as well as with less
comprehensive techniques, such as high-density oligo-
nucleotide microarrays.56 With NGS, however, the entire
sequence is read, and those changes that are not clini-
cally understood cannot be blocked out. One question
that is raised with any large-scale sequencing of the
human genome is the consideration for what to interpret
and report. For well-defined cases, such as the search for
a therapeutic target in a set of known cancer genes, the
levels of analysis and reporting are reasonably clear. In
diagnosing a rare disease through genome sequencing,
the presence of incidental findings becomes a more sig-
nificant topic. These issues remain under discussion, but
their solutions will no doubt involve an emphasis on coun-
seling and education before testing is performed, in-
formed consent with a clear explanation of the current
limits of testing and interpretation, maintenance of pri-
vacy and confidentiality, and sensitivity to culture within
families, their heritage, and their communities. As long as
a balance is struck between the promise and potential of
NGS testing and its current limitations, it can transition
from the research realm to the clinical setting, similar to
the many molecular genetic innovations that have pre-
ceded it.Analytical NGS Considerations
Regulation, Assay Validation, and Reference
Materials
Before making any new laboratory-developed test avail-
able for patient care, a clinical laboratory undertakes the
process of analytical validation. For Food and Drug Ad-
ministration–approved/cleared tests, the similar, but
more limited, required evaluation is termed verification.
However, Food and Drug Administration–approved/
cleared tests using NGS do not exist. In fact, there is
considerable uncertainty about the regulatory pathway
for NGS testing and resolution could take years. Thus,
laboratories will, for the foreseeable future, continue to
rely on regulations under the Clinical Laboratory Improve-
ment Amendment. The purpose of assay validation for a
laboratory-developed test is to document that the tar-
geted analyte(s) can be detected in a robust and con-
sistent manner. In accordance with Clinical Laboratory
Improvement Amendment regulations [Code of Federal
Regulations §493.1253(b)(2)], the following analytical
characteristics must be documented for this purpose: i)
accuracy, ii) precision, iii) analytical sensitivity, iv) ana-
lytical specificity, v) reportable range, vi) reference inter-
vals (normal values), and vii) any other performance
characteristic required for test performance (eg, carry-
over, dilutions, and calculations).
NGS ranges from a relatively limited scope to genome
sequencing. With exome sequencing, the coding regions
of the genome are interrogated, whereas with more com-
prehensive approaches to genome sequencing, inter-
vening regions are also included. In either case, how-
ever, the sequences are not truly complete because of,
for example, gaps in the obtained sequences, issues with
GC-rich regions, and bioinformatic limitations regarding
the calling of indel variants. These challenges can be
brought to light by a comparison with Sanger sequenc-
ing, but NGS presents a challenge to the notion of prov-
ing and documenting that the tested genome sequences
have been identified correctly. When validating a new
platform, conventional wisdom requires the laboratory to
compare the new approach with a gold standard. For
nucleic acid sequencing, however, that standard is the
traditional method of Sanger sequencing, the technical
capabilities of which are dwarfed by NGS. This recogni-
tion presents obvious dilemmas. It is practically not fea-
sible for a laboratory to perform Sanger sequencing of
whole genomes for reasons of reagent costs, labor, and
efficiency of both testing and analysis. Nevertheless, all
steps of NGS need to be evaluated, including sample
library preparation, clonal fragment amplification, the se-
quencing itself, and data analysis. For each of these
steps, quality control metrics need to be determined. The
question then arises whether the sequencing and docu-
mentation of representative portions of a reference ge-
nome would be satisfactory, or whether comparison to
online reference sequences could suffice. In addition, it
needs to be established what reference materials (RMs)
could be developed to make the validation process both
efficient and meaningful. An RM (commonly referred to as
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of whose properties and/or values are sufficiently homo-
geneous and well established to be used for the calibra-
tion of a measuring system, for the assessment of a
measurement procedure, or for assigning values to ma-
terials (International Organization for Standardization
15195).57 RMs are tested alongside patient samples and
allow laboratories to detect errors due to test system
failure or operator error. In addition, RMs are needed for
test development and validation, lot testing of new re-
agent batches, and proficiency testing and/or external
quality assessment programs. There is a lack of RMs for
NGS-based tests. The development of RMs for NGS of
panels of genes, exomes, or genomes will require a new
paradigm because it will no longer suffice to develop or
use a limited set of characterized gDNA samples that
represent most or all mutations in a single gene that
commonly cause a particular disorder.
There are several efforts underway to develop guid-
ance for laboratories regarding the application of NGS in
the clinical setting. The Division of Laboratory Science
and Standards at the Centers for Disease Control and
Prevention is working with stakeholders to develop useful
metrics to help define analytic and clinical performance
specifications of NGS assays. This project is addressing
test validation, quality control, and proficiency testing to
derive a set of principles and guidelines for the use of
NGS in the diagnosis of heritable conditions. The selec-
tion and use of appropriate reference materials is central
to all these themes and, therefore, the Centers for Dis-
ease Control and Prevention’s Genetic Testing Reference
Material Coordination Program (GeT-RM; http://wwwn.
cdc.gov/dls/genetics/rmmaterials/default.aspx, last ac-
cessed February 29, 2012) is engaging to generate re-
newable and publicly available characterized gDNA RMs
that can be used for clinical NGS testing. This need is
urgent because the pace of technology development in
NGS is so fast that conventional analytical validation
methods may not be feasible or realistic. It is envisioned
that gDNA from publicly available cell lines will be se-
quenced on multiple NGS platforms, after which the data
generated will be assembled into a consensus genotype
for each cell line. This will be posted in a publicly acces-
sible database and updated to reflect corrections to the
original sequence, should these be necessary. All Ge-
netic Testing Reference Material Coordination Program
efforts, including decisions about RM priorities, specimen
collection, cell line development, and mutation charac-
terization studies, occur through voluntary collaborations
with clinical laboratories and RM providers. The Clinical
Laboratory Standards Institute is in the process of revis-
ing its guideline, MM9: Nucleic Acid Sequencing Methods
in Diagnostic Laboratory Medicine.58 This document will be
substantially revised to address the use of NGS in the
clinical laboratory environment. The American College of
Medical Genetics has also established working groups to
develop recommendations relevant to the clinical use of
NGS. Finally, the College of American Pathologists is
developing checklist questions specific to NGS that will
be used in its accreditation program. It is expected that
the principles and recommendations developed fromeach of these groups will be in alignment, where there is
overlap, owing to an open information exchange and
many of the participants contributing to multiple efforts.
Bioinformatics Requirements
Only three major computations are performed with NGS
data: i) data assembly with base calling at the level of
individual reads, ii) alignment of the assembled se-
quence to a reference sequence, and iii) and variant
calling. Within variant calling, there may be different com-
putational analyses devoted to SNPs, small indels, struc-
tural variants or large indels, and copy number variants.
Despite the few major computations, NGS experiments
generate an unprecedented amount of medical data that
result in special informatics needs and require tools for
data management, storage, analysis, and archiving, both
to manage the large data set without error and to ensure
proper quality and documentation. Considering these
steps in greater detail, they can be delineated as follows:
i) image processing, ii) base calling and quality scoring,
iii) purity filtering, iv) quality control checks, v) alignment
to a reference sequence or de novo assembly, vi) SNP-
finding or application-specific steps (eg, chromatin im-
munoprecipitation or RNA sequencing), vii) packaging,
and viii) archiving.
Typically, analysis begins with a large set of tiled fluo-
rescence or luminescence images of a flow-cell surface,
which are recorded after each iterative round of sequenc-
ing. The next step is the most computationally intensive
part of the basic bioinformatics pipeline and comprises
the conversion of the image data into sequence reads,
termed base calling. During base calling, individual
beads or clusters are identified and localized in an image
series and parameters (eg, intensity, background, and
noise) are then used by platform-specific algorithms to
generate read sequences and quality scores for each
base.12 There is a continuing need to reduce error rates,
especially as platforms are pushed to generate longer
reads. As a result of the base calling process, FASTQ
files are generated. FASTQ files are usually platform spe-
cific and contain sequencing read data that combine
both the sequence and an associated per base quality
score. The sequence reads then are aligned to a known
reference sequence or assembled de novo. Mapping
many reads to the reference genome requires highly
efficient and accurate algorithms. The appropriate align-
ment method will depend on the sequencing platform,
data type, and computational resources.
One limitation of short–reads alignment and assembly
is the inability to uniquely align much of a read set.
Similarly, the number of reads is reduced when aligning
to larger, more complex genomes or reference se-
quences because of the higher probability of repetitive
sequences.59 Interestingly, error rates for individual NGS
reads are higher than for Sanger sequencing, which is a
reflection of the difference in methods. Even among NGS
platforms in use, error profiles vary. Nevertheless, the
accuracy of NGS is achieved by sequencing a given
region numerous times, which is facilitated by the mas-
sively parallel process. Assembly, alignment, and analy-
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ping reads for each nucleotide, or coverage depth. A
consensus sequence is derived through this process. In
practice, however, coverage across a sequenced region
is variable, and factors (eg, Poisson-like randomness and
amplification bias, differential ligation of adapters to tem-
plate sequences, and disparate amplification during
clonal template generation) may contribute to the ob-
served variability.60 Beyond sequence errors, inade-
quate coverage can cause failure to accurately detect
nucleotide variation, leading to false-positive and false-
negative results. Depending on the sequencing applica-
tion, the next step may involve quantification of reads,
mutation calling, copy number analysis, and/or analysis
of structural variations.
The NGS data deluge presents opportunities and hur-
dles for data analysis and management. One current
obstacle toward clinical translation is that most algo-
rithms in use need some programming expertise, to-
gether with specialized servers to handle and store all of
the data. The generation of user-friendly informatics tools
to effectively analyze NGS data will be essential to the
successful clinical application of NGS technology. To-
day, most users align the NGS reads to a known refer-
ence, such as the most current build of the genome,
using SNP databases to filter out alterations that are
known germ-line polymorphisms. In the analysis of men-
delian conditions, use of unaffected family members pro-
vides a useful background in which to identify novel dis-
ease-causing mutations. However, the calling of somatic
mutations in malignancies is much more complicated
because of the variance in ploidy and purity of the tumor
DNA, and is strongly dependent on the allelic fraction.
However, comparison to nontumor tissue from the same
patient provides an important tool for identification of
somatic mutations, although differentiation of cancer-
causing from passenger mutations remains challenging.
Elimination of false positives and negatives is critical for
both inherited and acquired diseases; however, although
elimination of false positives can largely be achieved
through verification by conventional PCR and Sanger se-
quencing, minimizing false negatives is less straightfor-
ward. And, even though the challenges in assigning re-
liable mutation calls, insertions/deletions, and structural
variations are considerable, the main challenge ultimately
may well lie in distinguishing clinically relevant mutations
from benign variants. With respect to data storage, typi-
cally tens or hundreds of giga bp of short reads can be
generated during one NGS run. As a result, the average
NGS experiment generates terabytes of raw data, requir-
ing a vast data storage and management solution. The
image files, in fact, require the most storage capacity,
and many researchers opt to delete these files once the
base calling has been completed. Thus, only the FASTQ
or just the postalignment files are stored. Clinical labora-
tories are required to maintain certain data from the tests
that are performed to verify their test results, but the
extent of data that need to be retained from NGS assays
has not been established. The challenge to laboratories
is that the retention of the complete data is costly and, in
many instances, cost prohibitive. Possibly, one way ofovercoming the need to obtain expensive servers may be
the use of cloud computing.54
From the perspective of the electronic health record
(EHR), NGS test results reporting raises several issues.
Still, it is important to clarify that several aspects of ge-
netic or genomic testing, regardless of the method, can
be supported by EHRs that provide the architectural
framework. These aspects include the ordering of the
test, the receiving of a document that summarizes the
clinical interpretation, and storage of the interpretation.61
Although there are many potential ways to integrate NGS
data into the EHR, three issues seem to consistently
emerge within this context. First, there is debate about
whether the EHR should store the large, raw data files,
given that the EHR is the legally binding medical record.
In general, the information in the EHR has been inter-
preted by the appropriate diagnostic expert. Similar stor-
age issues arise when considering magnetic resonance
images; typically, these images are stored in archives
that are linked to, but separate from, the EHR. Second, it
is questioned to what extent the EHR should assist diag-
nosticians in interpreting NGS results. The software in-
volved in interpreting raw data (eg, calling bp) is gener-
ally tightly coupled to the instrumentation platform, not
the EHR. A variety of software capabilities can be used to
compare a patient-generated sequence with a reference
sequence and to identify variations with a likely functional
impact. Current and future variant databases may help
the diagnostician determine whether a variant is novel.
The capability of linkage to such variant databases is the
most probable extent of direct access in the context of
the EHR. Finally, there is discussion of the role of the EHR
in sharing new knowledge when it becomes available
after the formal interpretative report is completed. The
EHR is intended to enable compliance with the opera-
tional regimen of the end users, and each organization
using an EHR is obligated to reach its own conclusions
about potential incorporation of new knowledge. The
technology required to enable dynamic interpretation of
NGS results is feasible but will take significant develop-
ment before it is ready for implementation. Perhaps the
most likely context in which dynamic interpretation will
occur is outside the context of the EHR in the less-regu-
lated framework of the personal health record. Already,
some direct-to-consumer companies regularly adjust
their content based on newly emerging knowledge, al-
though these reports are not considered to fall within the
legally binding diagnostic model. In the clinical labora-
tory, it also may actually be more economically feasible to
resequence (subsets of) genomes than to regularly up-
date the EHR or to store large data files indefinitely, which
would obviate some of these bioinformatics concerns.
Resequencing also allows for the benefits from NGS
technology improvements, which may enhance the data
generated, such as the extent of the genome sequenced
or the depth of coverage for each nucleotide position.
Bioinformatics Quality Assessment
Similar to CE-based methods, the quality of NGS images
is digitally evaluated using components such as signal
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their ratios, signal strength relative to neighboring calls,
and other similar metrics. Based on a combination of
these parameters and image-processing adjustments
(eg, dye cross talk corrections and/or phasing correc-
tions), the particular image is assigned a base call and a
quality score that indicate the likelihood that the base call
is correct. In CE analyses, this is typically called a Phred
score and is generated on a logarithmic scale (Q  10
log E, and E  probability of error), so that a Phred of 10
means a 1/10 probability of error, whereas a Phred of 20
indicates a 1/100 probability that the call would be in
error. Thus, the higher the score, the more confidence
can be placed in the call. An obvious way to evaluate
scoring accuracy is to take a known reference sequence
and to sequence it using NGS technology at great depth.
In the course of sequencing, the same positions will be
called at various Phred (or Q) scores in multiple, inde-
pendent sampling events, after which the data can be
plotted so that the score assigned to any call based on
the nucleotide calling software can be compared with
what was actually observed based on the known call at
that position. Once confident that a score reflects the
quality of the data accurately, thresholds can be deter-
mined and data can be filtered accordingly. For se-
quencing information, the Clinical Laboratory Standards
Institute has recommended filtering on a Phred score of
20 to 30,58 resulting in an error rate of 1/100 to 1/1000.
When interrogating variants in a population-level situa-
tion, such as microbes or tumor samples, higher thresh-
olds may be necessary.
Each platform is characterized by its own error profile.
Some platforms have insertion or deletion errors during
homopolymer runs, whereas others have an increased
likelihood of sequence errors toward the end of the
read.9–13 Data production and output also differentiate
platforms. An example of this is color space (a color
represents a class of dinucleotides, such as AA, CC, GG,
or TT), as opposed to base space (a series of bases
represented by A, C, G, and T calls). These platform
differences must be addressed at the algorithmic level.
When analysis tools take these aspects into account,
some sequence errors are correctable.62
Once a subset of individual calls has passed the base-
calling filter, the specific sequence fragments must be
assigned to the reference genome (in the case of whole
genome sequencing, this is typically NCBI 37). The ref-
erence genome in National Center for Biotechnology In-
formation is derived from a few individuals and is a small
sampling of human genetic variation. It also contains rare
and common disease risk variants complicating the de-
tection of these risk alleles. There are efforts to build
major allele reference sequences that should be consid-
ered for accurate ethnically concordant variant calling.63
For large data sets, such as whole genome reconstruc-
tion, speed becomes critical, and a tiered approach to
sequence alignment is taken. First, the sequences that
align based on some subset of the total read are as-
signed a quality score based on how well they align to the
reference, taking into account such components as the
number of mismatches relative to the reference. The ex-pectation is that most sequences will have only a limited
amount of variation relative to the reference sequence.
Second, for the subset of samples that were not success-
fully placed using the first round of alignment criteria, a
multispeed gapped alignment approach is taken. For this
subset of sequences, gaps are introduced to evaluate
whether this will allow for improved alignment and assign-
ment of the sequence; if on introducing a gap somewhere
in the sequence both regions align with high fidelity to the
reference, the gap is retained. Details of this process
differ among alignment algorithms. Therefore, it is impor-
tant to consider the appropriate performance parameters
and the user manuals when choosing alignment algo-
rithms. After this step, probability values are assigned
based on all possible alignment solutions, and the best
alignment is kept and assigned a score based on the Q
scoring scale. Various alignment algorithms exist with
various penalties or thresholds for the fidelity of sequence
alignment to the reference. Also, algorithms vary to their
effectiveness for detecting specific types of sequence
variations, such as SNPs and indels. This may require
use of more than one aligner to derive optimal results
when calling sequence variants. For clinical applications,
conservative approaches are most appropriate because
high confidence should exist when making a call.
When all of the sequences that passed the initial base
calling and sequencing filters have been aligned and
stacked, a consensus call is made. This step represents
a significant departure from CE sequencing methods,
because in those cases, a PCR is sequenced and both
alleles are typically imaged simultaneously. Although this
can cause a heterozygous signal to appear with dimin-
ished quality (and, at times, the calling software is unable
to call these positions without human intervention), in
NGS methods, each molecule is sequenced indepen-
dently and, therefore, there is not a mixed signal. How-
ever, because of the fact that each molecule is se-
quenced independently, the probability of detecting a
second allele in a heterozygous position is dictated by
the sampling probability:
P(x, p, N)
Kx
NX N!
(X ! )(N X)!
pXq(NX)
In essence, the sampling question being asked is the one
encountered in school: if given a bag of marbles and told
that the bag contains either all blue marbles or half blue
and half yellow, then how many marbles do you need to
draw to have 99% confidence that you would detect both
colors if they were both present? In this case, we assume
that, in a heterozygote, approximately half the alleles
should be one nucleotide and half the other. However,
the second allele should be observed more than once;
thus, if, for example, second allele needs to be present in
at least 20% of the calls to make a heterozygous consen-
sus call, then by applying these numbers into the previ-
ously described formula, that position needed to be sam-
pled at least 18 times to be at least 99% confident of
detecting both alleles, if present. K establishes the lower
bound of the interval over which the probabilities need to
be summed. In this case, we set this as 20% of the total,
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each allele at least twice and not more than eight times,
so k 2 and we would sum the probabilities of observing
two, three, four, five, six, seven, and eight times. The
consensus call is typically made based on a quality score
that represents a combination of the following: i) the num-
ber of times that the position has been sampled in inde-
pendent sequencing events, ii) the quality of each of the
base calls made, and iii) the quality of the alignment.
However, again, the score assigned represents an op-
portunity to apply a quality filter so that only calls with
high raw data quality, high alignment confidence, and a
high level of confidence in the variant call will be kept for
further analysis and interpretation.
The number of reads that align to a given reference
sequence region is referred to as coverage. Operation-
ally, the amount of coverage obtained is dependent on
the amount of sequencing performed versus the target
size. The human haploid genome is approximately three
billion bases, and most investigators aim for 30- to 40-fold
average coverage because the cost of sequencing re-
mains a limiting factor. Depending on the capture probe
reagents used for exome enrichment, the target size var-
ies from 30 to 50 Mb. Exome coverage will vary depend-
ing on the amount of sequencing, but typical average
exon coverage would be 50- to 100-fold. Gene panel
target sizes vary considerably, depending on the number
of genes. Average coverage, however, is in the same
range as for exon sequencing when analyzing for consti-
tutional variants. In comparison, a higher average cover-
age (500-fold) is aimed for when attempting to detect
low-frequency alleles in mixed population analyses, includ-
ing somatic variants in tumor samples. Although average
coverage is one metric to determine, it is essential to also
define the range of coverage for targets being sequenced,
to characterize the adequacy of sequencing for a given
region. A balance exists between increasing coverage to
improve variant detection and increasing sequencing
costs. The lower coverage for genomes can lead to
missed variants that are observed in exome sequencing
results from the same individual. Conversely, modestly
more exons are interrogated by genome compared with
exome sequencing, because of the fact that some exons
are not enriched by exome capture. Gene panel se-
quencing offers the ability to achieve high levels of cov-
erage in a defined target set. Although an attractive ap-
proach, gene panels are limited in that adding new genes
to the panel typically requires a panel redesign.
Once a position has been called according to the
bioinformatics quality thresholds imposed, the clinical im-
plications of the variants that were called need to be
evaluated. This generally involves querying all of the calls
made in the genome sequence against all known relevant
databases that associate variants of clinical significance
with the published reports. The first challenge is mapping
the clinical variants, which are often reported using Hu-
man Genome Organisation (International) nomenclature
(which is gene centric),64 to their genomic coordinates
relative to the National Center for Biotechnology Informa-
tion reference genome sequence. Once this has been
accomplished, it is fairly straightforward to query all po-sitions against the genome sequence and to report the
calls made. When a definitive call carries a clinical impli-
cation, the typical interpretive approach used in clinical
laboratories for traditional sequencing methods is appro-
priate. However, compared with targeted genetic testing,
interpreting much of an entire genome poses a substan-
tially larger challenge because many more variants will
be detected. The lack of any database curated to ac-
cepted clinical standards likely presents the most signif-
icant challenge in managing and reporting genome se-
quencing data.
Postanalytical NGS Considerations
Practical Interpretation and Reporting
There is a paucity of standardized best practice guide-
lines or criteria for the technical and clinical implementa-
tion of genome sequencing. However, it is an extension of
current genetic testing practices and, as such, can be
realized more completely as our understanding of
genomic variation becomes more advanced and practice
guidelines that address the optimal interpretation (or
combinations of) variants in an individual have been de-
fined. Apart from genetic test modalities, genome se-
quencing requires the use of a sound biocomputational
infrastructure. Toward this end, there is a need for stan-
dardized bioinformatics pipelines for refinement in base
calling and annotation of the variants obtained for their
likely functional consequences. Furthermore, high and
consistent levels of coverage are required between avail-
able platforms to ensure accuracy in nucleotide base
calling. Interpretations resulting from any WGA platform
must account for the analytical limitations of the specific
technology or platform being used. An additional layer of
complexity is that genome sequencing must be inte-
grated with complementary testing tools. An expert inter-
pretation of the meaning associated with the vast
amounts of data that result from these types of analyses
will be essential. These interpretations may require con-
sideration of ancillary factors, such as the patient’s age,
sex, clinical presentation, and family history. Other rele-
vant variables that also must be considered include the
following: i) the incomplete ascertainment of structural
variations in the human genome, ii) lack of accurately
curated haplotype data, iii) variable expression of the
disease phenotype, iv) disease-associated penetrance,
v) gene-environment interactions, vi) heritability, vii) iden-
tification of rare mutations of unknown significance, and
viii8) genetic heterogeneity (locus and allelic).65,66 There-
fore, the interpretation and reporting of genome sequenc-
ing results requires a team approach, whereby patholo-
gists, geneticists, and other laboratory professionals
become even more directly involved with the health care
team to bridge the inevitable gap in knowledge between
those closely involved with genomic data interpretation
and the health care providers who would be hard pressed
to keep up with the new developments but who need to
integrate the information into their medical practice. These
clinicians will require competent expert guidance in their
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hance their patient care. This will accelerate the need for
development of new counseling paradigms that appropri-
ately balance new information with the uncertainty about the
meaning of a test result.66
Part of the challenge of providing expert interpretation
of genome sequence data is the evolving nature of our
understanding of the meaning of differences between
individual genomes. Genotype-phenotype uncertainties
continue to confront us in the setting of monogenic dis-
orders, and making sense of combinations of sequence
variants across genes is even more challenging because
of the plethora of variations in biological effects, including
those on protein function and interactions within and be-
tween pathways. A logical approach to this complex is-
sue is to initially reduce genome sequence data to focus
on a subset of sequence variants that are likely to be
clinically significant. Even this approach, however, re-
quires the accumulation of a large set of high-quality and
ethnicity-specific reference genomes that can be used
for genomic comparisons. It also will require the availabil-
ity of clinically vetted, regularly updated databases of
annotated variants that ideally would include population
frequencies and referenced clinical relevance for each
sequence variant. Thus, there is a need for consolidation
of the various genotype-phenotype databases available
into a commonly available and perhaps centralized clin-
ical-grade resource that is publically accessible.
Proficiency Testing/Alternative Assessment
Proficiency testing and alternative assessment refer to a
periodic laboratory evaluation of characterized speci-
mens to determine assay variability and for the purpose
of comparison to a standard measure, when one exists.
Proficiency testing, but not necessarily alternative as-
sessment, requires that specimens be provided and the
evaluation administered by a third party for the purpose,
in part, of providing an interlaboratory comparison. In the
United States, laboratories are required to demonstrate
proficiency through participation in proficiency testing
programs or through otherwise establishing a means for
alternative assessment.67 Proficiency testing is a well-
recognized component of an overall quality management
system integral to regulatory oversight68–70 (College of
American Pathologists; http://www.cap.org, last ac-
cessed February 29, 2012).
Proficiency testing and alternative assessment have
become more challenging as mutation panels have ex-
panded. For example, current surveys for the molecular
genetic testing of cystic fibrosis interrogate mutations
performed by many laboratories (http://cap.org, last ac-
cessed February 29, 2012) but not necessarily full gene
sequencing. Thus, even for relatively few mutations, pro-
ficiency testing challenges cannot fully address all tests.
The use of DNA sequencing in the clinical laboratory has
raised additional challenges because no proficiency test-
ing or alternative assessment scheme is practically ca-
pable of assessing all possible results. This has been
addressed through generation of a method-specific, as
opposed to an analyte-specific, scheme in Europe.71,72More recently, the College of American Pathologists has
added a similar, multitiered sequencing challenge to its
proficiency testing program (http://www.cap.org, last ac-
cessed February 29, 2012).
Regarding NGS, no proficiency testing is available in
the United States. Because of the quantity and variation
of data recovered from these assays, schemes that are
based on NGS (as a group of methods), rather than on
individual genes, are likely to be pursued. It is reasonable
to envision that a general scheme can be developed in
which the proficiency testing/alternative assessment of
blinded samples may vary, depending on the actual ap-
plication. In the near term, laboratories engaging in NGS
are likely to use sample exchanges or blinded retesting of
previously tested samples as a means of performing al-
ternative assessment.70 If a method-based scheme
emerges, particular consideration should be paid to the
kinds of variants that are intended to be detected by a
given test. For example, the ability to detect substitutions,
insertions, deletions, inversions, and copy number varia-
tions should be considered and proficiency testing for
each category of variants intended to be detected by the
method should be assessed. A further significant chal-
lenge is in developing measures for acceptable perfor-
mance, including considerations of acceptability thresh-
olds for limited versus comprehensive testing, such as for
selected gene panel sequencing as opposed to genome
sequencing.
Professional Considerations
Reimbursement
The payment (reimbursement) and coverage experience
in molecular pathology has been bemoaned by both lab-
oratories and payers over almost two decades. The trans-
parency of services performed by laboratories, particu-
larly in the areas of inherited diseases, oncology, and
histocompatibility, has been particularly problematic for
payers because of the analytically precise, but clinically
opaque, way in which services are coded, using a uni-
versal group of current procedural terminology (CPT)
codes that describe individual technical steps (eg,
identification by DNA sequence analysis, 83904) that
compose an assay. That same 83904 code is a com-
ponent of all sequencing assays, regardless of the
purposes for the tests. Moreover, because DNA se-
quencing assays require amplification of multiple ex-
ons for sequencing, 83904 and other technical codes
are (appropriately) submitted in multiple units of ser-
vice. Hence, payers are presented with code stacks
that do not indicate the condition for which the se-
quence analysis was performed.
A special work group of the American Medical Asso-
ciation CPT Editorial Panel, working off a white paper
from the Association for Molecular Pathology (AMP) Eco-
nomic Affairs Committee, has recently released the
framework of a solution for this major shortcoming in
molecular pathology coding. Two groups of category 1
codes are proposed to replace the stacking codes
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first group (tier 1) provides individual CPT codes for spe-
cific tests performed in high volume or desired by payers.
Taking cystic fibrosis as an example, individual codes
would be available for high-volume screening assays for
common mutations, as well as for full gene sequencing,
deletion/duplication analysis, and even analysis for
known familial mutations or the CFTR intron 8 poly (TG)T
repeat unit. The second group (tier 2) is a series of nine
codes that include many of the less commonly performed
tests, divided according to increasing amounts of tech-
nical and professional resources. For example, level 4
includes tests that require sequencing of a single exon of
a gene (as in testing a relative for a known familial muta-
tion), whereas level 9 is for full sequencing of genes with
50 exons. A not otherwise specified code (ending in 99)
will still exist in the 80000 CPT series reserved for new
and emerging technologies. An expert group of individ-
uals with process and technical expertise will advise the
CPT Editorial Panel on whether new tests should receive
their own CPT code or be placed in one of the nine tier 2
codes with other assays of similar complexity. A code
proposal typically takes 15 to 24 months for review and
approval by the CPT Editorial Panel.
With the transition of NGS to the clinical laboratory, the
question of payment for NGS testing arises. This question
presupposes that such tests will be widespread and clin-
ically useful, which is a requirement for approval of a
category 1 CPT code. Published peer-reviewed evidence
of medical utility will be important for the CPT Editorial
Panel to approve codes, as well as for payers to agree to
pay for tests such as genome, exome, or transcriptome
analyses. Payers already cover some multigene se-
quencing panels performed by Sanger or microarray-
based sequencing. For reasons of cost and complexity
of data analysis, these types of targeted tests are likely
to be the leading edge of NGS applications for coding
and reimbursement. With rapidly decreasing technical
costs, it is not unrealistic to consider that exome or
ultimately genome sequencing may become the de-
fault testing method for a wide range of clinical pur-
poses, with interpretation initially focused on specific
multigene panels and possibly blinding the balance of
genomic variants.
Although software tools are essential to assemble and
provide initial analysis of raw NGS data, interpretation for
clinical use will require professional training and judg-
ment. This effort will be the most time-consuming and,
therefore, costly component of the testing and may be a
significant cost for the laboratory, if this is where the
interpretation occurs. Hence, NGS billing codes should
reside on the physician fee schedule, with a component
for professional services. Although this will not be an
issue for physicians, laboratory genetics providers with
doctoral training who obtain independent board certifica-
tion are not yet eligible to bill professional component
services on the physician fee schedule. A multistake-
holder coalition is attempting to resolve that issue. New
payment models based on episodes of care would, over
time, presumably include NGS tests based on evidencethat these contribute meaningfully to patient manage-
ment and outcomes.
Gene Patents and Genome Sequencing
Utility patents are a specific subtype of intellectual prop-
erty that give their owners the right to exclude others from
making, using, offering to sell, or selling an invention in
the United States or importing an invention for the life of
the patent,73 which is typically 20 years.74 Patents can be
awarded for novel, nonobvious, and useful processes,
machines, manufactures, and compositions of matter.75
Despite judicial doctrines that prohibit the patenting of
products of nature and natural phenomena,76,77 the US
Patent Office has granted thousands of patents on hu-
man gene sequences, variants, and associations be-
tween gene variants and clinical phenotypes78 because
US patent law has generally regarded isolated DNA as a
complex chemical, instead of a product of nature. In
addition, patents on genotype-phenotype associations
have been awarded when claims include correlation
steps that generically frame the biological relationships
as processes.79
Patents on human gene sequences, if ultimately valid,
could present an enormous barrier to the incorporation of
genome, exome, and transcriptome sequencing into
medical practice. Making, using, or selling a patented
invention without the consent of the patent holder consti-
tutes patent infringement. Genome sequencing by its
nature potentially appears to involve infringement of nu-
merous gene sequence patents, irrespective of the clin-
ical use of the information obtained. Moreover, clinical
application of the sequence information would also likely
infringe on thousands of genotype-phenotype associa-
tion patents. Although theoretically the data from pat-
ented genes during genome sequencing and interpreta-
tion could be blinded, this would greatly diminish the
usefulness of the test results. Perhaps through the forma-
tion of gene patent pools, an affordable system of com-
mon access to genes and genetic information ultimately
could be developed. However, valuation of thousands of
individual genes and genetic relationships would prove
problematic. When coupled with evolving knowledge and
the continual need for the addition of new genetic rela-
tionships to this pool, the challenges associated with
implementation appear daunting.
In Association for Molecular Pathology v United States
Patent and Trademark Office, a lawsuit sponsored by the
American Civil Liberties Union, several medical societies,
health care providers, breast cancer patients, and wom-
en’s groups sued Myriad Genetics and the Patent Office,
seeking to invalidate key claims of patents covering the
wild-type and mutated sequences of the BRCA1 and
BRCA2 genes, as well as associations between those
sequences and the predisposition to breast and/or ovar-
ian cancer. In a landmark decision, the court held that
both composition of matter claims on the human BRCA1
and BRCA2 gene sequences and process claims cover-
ing the correlations between mutations in these genes
and a heritable predisposition to breast cancer are in-
valid. However, this ruling was partially overturned on
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entability of human gene sequences and genotype-phe-
notype associations will eventually be decided by the US
Supreme Court. Association for Molecular Pathology v
United States Patent and Trademark Office, therefore, will
have profound implications for the clinical application of
genome sequencing.
Genomics Education
The human genome can be likened to a new human
organ system for which current medical training provides
rudimentary education at best. As with any field of med-
icine, it is imperative that ongoing and continuing medical
education be used to learn about new modalities and
emerging technologies that reflect current practice. No
single program or fellowship can be expected to com-
prehensively train its residents, given the dynamically
evolving milieu. However, it is essential to provide train-
ees with a good grasp of the current concepts while
exposing them to a broad range of educational opportu-
nities. Professional organizations, such as the AMP, the
College of American Pathologists, and the American Col-
lege of Medical Genetics, are working on various aspects
of this, as are individual training programs. Within pathol-
ogy and medical genetics training programs, molecular
genetic pathology and clinical molecular genetics fellow-
ships provide the most intense training in molecular test-
ing, which can lead to board certification through the
American Board of Pathology or the American Board of
Medical Genetics. Anatomical and clinical pathology res-
idency training programs are required to provide molec-
ular pathology training for all residents, as reflected by
the inclusion of molecular pathology questions on the
pathology board examinations. However, the extent of
molecular pathology education within residency pro-
grams is variable. Practicing pathologists and clinical
laboratory geneticists have a wide range of molecular
knowledge, depending on their past training, length of
time in practice, practice setting, and the types of con-
tinuing medical education and lifelong learning in which
they have participated. Genomics and genome testing
are just beginning to be integrated into existing training
programs; however, without doubt, these practices will
increase in prominence in the near future.
How do we transition to the incorporation of genomics
into pathology training and practice? A group of pathol-
ogy and genetics societies has formed a working group
called Training Residents in Genomics, which is devel-
oping a pathology residency genomics curriculum that
can be adopted by any pathology residency training
program. The curriculum will consist of a set of Power-
Point lectures, practical exercises, and literature refer-
ences that will be available on the Internet. A similar
initiative of an online genomics course, which will be
made publicly available, has been developed at Stanford
University (Stanford, CA). Clearly, these programs will
provide basic genomics training to pathology residents
and pathologists in practice, but will not be sufficient for
the actual practice of genomics and use of NGS for
clinical testing, or even for the proper interpretation ofspecific genomic results within the context of pathology
practice. Broader inclusion of genomic test results into
the remainder of pathology education will be required to
more completely integrate NGS education. Another op-
tion for pathology residency training is to develop tracks
with a genomics training focus, while maintaining the
broader educational requirements of anatomical and clin-
ical pathology training. For training in the performance
and interpretation of large-scale genomic tests, molecu-
lar genetic pathology fellowship programs will probably
continue to offer the best option for intensive training.
After all, this type of testing is the next logical progression
for the practice of molecular pathology and will likely
replace many current molecular tests as the technology
becomes less expensive. This transition could be driven
by changes in the Accreditation Council for Graduate
Medical Education requirements for molecular genetic
pathology fellowship programs. For practicing patholo-
gists, continuing medical education programs in the use
of genomics, as applied to specific types of pathology
practice settings, are available from several sources but
will need to be expanded as the use of genomics and
NGS increases.
Genomics education also is needed outside the prac-
tice of pathology. For other medical specialties, patholo-
gists can act as the resource for the proper use and
interpretation of genomic test results for patient care, as
is already the case for all pathology testing, but only if
pathologists truly understand this testing. In addition,
each medical specialty will incorporate genomics as-
pects significant to its specialty into its educational path-
ways. Medical education also needs to incorporate
genomics education into the medical school curriculum.
With the revisiting of the Flexner Report in 2010, many
medical schools are assessing and revising their curri-
cula, with the opportunity to incorporate and emphasize
the use of human genome data into medical practice and
patient care. Finally, genomics education and literacy for
patients, their families, and the public will assist with the
acceptance of genomics into medical care. Patient and
family education can be addressed within specific med-
ical practice settings and through disease-based support
organizations, whereas public education may be ad-
dressed prospectively through K-12 and undergraduate
education curriculum enhancements and through public
education campaigns.
Future Applications and Implications of NGS
To predict the future, we can only try to seek lessons from
the past. As prescient and understated as Watson and
Crick were when they wrote “It has not escaped our notice
that the specific pairing we have postulated immediately
suggests a possible copying mechanism for the genetic ma-
terial,”80 could they have imagined how the golden age of
molecular biology would lead to molecular diagnostics?
Since then, molecular biology has progressed to se-
quencing short DNA sequences in experiments that took
days1–3,81 and evolved to sequencing individuals’ ge-
nomes in a similar, indeed shorter, time frame. Given the
dramatic technical progress in transportation, communi-
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proximately 60 years, going from the elucidation of the
double helix to sequencing entire genomes may have
been a logical evolution, but only in hindsight.
Now that much of the genome is already available for
technical interrogation by NGS, multiple new diagnostic
opportunities exist for molecular pathologists and their
patients. Examples are already beginning to abound (eg,
in molecular cardiology,11 molecular oncology,82 and
noninvasive trisomy detection83–85). The list of potential
applications is limited only by our imaginations. Molecu-
lar pathologists and geneticists have been professional
diagnosticians of genetic and now genomic conditions
and have interpreted the data generated in clinical mo-
lecular laboratories since the field’s inception. They serve
as expert analysts and consultants to other physicians
and will continue to do so as dependable stewards of
these new technologies. Molecular pathologists and lab-
oratory geneticists, in partnership with other genomics-
trained clinicians and health care professionals, are es-
sential to ensuring that these test results are obtained,
used, and reported responsibly. The AMP and its mem-
bers play a pivotal role in this area of molecular diagnos-
tics and in its future. AMP members comprise the largest
proportion of those setting the framework for the use of
NGS and genome testing by developing and offering
these services. In thinking strategically, AMP and its
members are well positioned to productively collaborate
with other pathology and genetics societies to author
practice guidelines and to recommend quality assess-
ment monitors and metrics. The evolving technology in-
novations are rapidly reducing the cost of materials and
instrumentation, to the point at which many laboratories
are considering leapfrogging from single-variation testing
to NGS methods that evaluate much of the genome.
Notably, although the costs of performing the assays
have decreased, the fundamental process of applying
clinical expertise to the interpretation of the identified
variants remains largely unaltered and remains central to
our contributions to patient care.
AMP, through its diverse expert membership, is
uniquely positioned to proactively address these issues
and to inform the development of proficiency testing and
alternative assessment schemes necessary for ensuring
the quality of clinical NGS testing. AMP is advancing the
issues that are presented, and is shaping the landscape
in a collaborative process with other professional organi-
zations to accomplish the goals of excellent medical
practice in the genome era. Now no longer an abstract
concept for the future, the exciting reality of powerful
genome testing has decisively arrived.
Disclaimer
The Association for Molecular Pathology (AMP) Clinical
Practice Guidelines and Reports are developed to be of
assistance to laboratory and other health care profes-
sionals by providing guidance and recommendations for
particular areas of practice. The Guidelines or Report
should not be considered inclusive of all proper ap-proaches or methods, or exclusive of others. The Guide-
lines or Report cannot guarantee any specific outcome,
nor do they establish a standard of care. The Guidelines
or Report are not intended to dictate the treatment of a
particular patient. Treatment decisions must be made
based on the independent judgment of health care pro-
viders and each patient’s individual circumstances.
AMP makes no warranty, express or implied, regarding
the Guidelines or Report and specifically excludes any
warranties of merchantability and fitness for a particular
use or purpose. AMP shall not be liable for direct, indi-
rect, special, incidental, or consequential damages re-
lated to the use of the information contained herein.
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